Deracoxib (CAS No 169590-41-4) is a non-steroidal anti-inflammatory drug (NSAID) that primarily belongs to the COX-2 inhibitor class used in biomedical research to understand its selective inhibition mechanism Originating as a therapeutic for canine osteoarthritis Deracoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme reducing inflammation and pain while minimizing gastrointestinal side effects commonly associated with non-selective NSAIDs Its in vitro activity typically ranges in the nanomolar to low micromolar range depending on the assay conditions Deracoxib is frequently employed in cell models and animal studies to investigate its anti-inflammatory analgesic and potential anticancer properties It s also used in drug screening to explore COX-2 inhibition pathways Experimental concentrations typically depend on the specific research design as determined by study goals and model specifics